Higher-Than-Expected Rates of Lactic Acidosis Among Highly Active Antiretroviral Therapy-Treated Women in Botswana
Lactic acidosis
Mitochondrial toxicity
Hyperlactatemia
Interquartile range
Stavudine
DOI:
10.1097/qai.0b013e3181568e3f
Publication Date:
2009-03-03T22:04:46Z
AUTHORS (16)
ABSTRACT
Background: The ability of nucleoside reverse transcriptase inhibitors (NRTIs) to inhibit human mitochondrial polymerase-γ results in impaired synthesis enzymes that generate adenosine triphosphate (ATP) by oxidative phosphorylation. This has been associated with several long-term toxicities, which include lactic acidosis and pancreatitis, peripheral neuropathy, lipoatrophy. Methods: Enrolled highly active antiretroviral therapy (HAART)-treated adults have completed nearly 2 years follow-up as part the ongoing randomized clinical trial Adult Antiretroviral Treatment Drug Resistance (Tshepo) study. All patients were intensively screened for presence ARV-related toxicities. Results: Six hundred fifty (69% female) initiated on NRTI-based HAART. Overall, 2.0% developed moderate severe symptomatic hyperlactatemia, 7 (1.0%), all female, diagnosed acidosis. Female gender (P = 0.008) being overweight, namely having a body mass index (BMI) greater than 25 0.001), predictive development hyperlactatemia or Older age (age >40 years) showed statistical trend 0.053) predictor toxicity, whereas exposure d4T and/or ddI 6 more months was not 0.102). Those had mean BMI 32.38 (interquartile range [IQR] 29.4 35) at time toxicity receiving HAART 12.1 (IQR 20.8). Four (57%) died hemorrhagic pancreatitis; these 4 also comorbid diagnosis pancreatitis grade 3/4 lipase elevations abdominal symptoms their demise. Conclusions: Rates appear be higher southern Africa when compared rates previously described elsewhere. Risk factors multifactorial but female 25. Additional studies are evaluate other possible risk factors, such host genetic differences.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (23)
CITATIONS (55)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....